Vascepa (icosapent ethyl) is a prescription medication used to lower high triglyceride levels in adults. According to Drug Patent Watch [1], Vascepa is suitable for patients with cardiovascular risk who have elevated triglyceride levels. The drug is approved by the FDA for use in adults with triglyceride levels above 150 mg/dL who are on a statin medication.

A clinical trial published in The New England Journal of Medicine [2] evaluated the efficacy of Vascepa in reducing cardiovascular events in high-risk patients. The study found that Vascepa significantly reduced the risk of major cardiovascular events, including heart attacks and strokes, in patients with elevated triglyceride levels who were already receiving statin therapy. However, it is important to note that the study population had specific inclusion and exclusion criteria, and the results may not be generalizable to all patients with cardiovascular risk.

The official Vascepa website [3] states that the drug may not be suitable for everyone, and patients should discuss their medical history and current medications with their healthcare provider before starting treatment. Additionally, the website notes that Vascepa may interact with certain medications, and patients should inform their healthcare provider of all medications they are taking.

In summary, Vascepa is suitable for patients with cardiovascular risk who have elevated triglyceride levels and are already receiving statin therapy. However, patients should discuss their medical history and current medications with their healthcare provider before starting treatment, as Vascepa may not be suitable for everyone and may interact with certain medications.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.nejm.org/doi/full/10.1056/nejmoa1812792
[3] https://www.vascepa.com/